Phenominer Database Results (45 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Site Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Method Notes Clinical Measurement Notes Record ID Study ID
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 16 87.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67853 829
DA.ACI-(D10Rat2-D10Rat6) experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 18.9 d 2.2 6.22 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68206 829
DA.ACI-(D10Rat2-D10Rat6) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 87.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68207 829
DA.ACI-(D10Rat10-D10Rat142) experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 6 13.5 d 3.1 7.59 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68218 829
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 7 0.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68733 829
DA.ACI-(D10Rat12-D10Rat144) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 13 53.8 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67876 829
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 13 76.9 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67859 829
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 10 40.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67856 829
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 87.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68201 829
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 37.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68204 829
DA.ACI-(D10Rat10-D10Rat142) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 7 71.4 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68219 829
DA.ACI-(D10Rat12-D10Rat144) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 13 38.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days relap, % 68222 829
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 14 18.5 d 1.6 5.99 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68224 829
DA.ACI-(D10Rat15-D10Rat29) experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 5 13.4 d 2.0 4.47 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68203 829
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 14 13.4 d 2.2 8.23 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68209 829
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 100.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67850 829
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 16.4 d 2.6 7.35 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68200 829
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 16 56.3 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68210 829
DA.ACI-(D10Rat2-D10Rat29)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 1 3.0 d 0.0 0.0 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68730 829
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 7 14.3 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68734 829
DA.ACI-(D10Rat12-D10Rat144) experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 7 14.4 d 2.8 7.41 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68221 829
DA.ACI-(D10Rat219-D10Rat29) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 16 25.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days expressed as a fraction of total number of animals 68231 829
DA.ACI-(D10Rat219-D10Rat29) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 16 81.2 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67874 829
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 16 81.3 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68225 829
DA.ACI-(D10Rat10-D10Rat142) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 7 85.7 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67875 829
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 13.0 d 1.8 5.09 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68197 829
DA.ACI-(D10Rat219-D10Rat29) experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 6 11.5 d 2.6 6.37 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68215 829
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 37.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68732 829
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 12 33.3 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67848 829
DA.ACI-(D10Rat2-D10Rat6) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 100.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67860 829
DA.ACI-(D10Rat15-D10Rat29) experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 12 3.5 d 1.7 5.89 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68194 829
DA.ACI-(D10Rat2-D10Rat29)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 6 13.3 d 2.6 6.37 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68731 829
DA.ACI-(D10Rat15-D10Rat29) experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 10 8.6 d 1.5 4.74 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68227 829
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 13 30.8 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days relap, % 68228 829
DA.ACI-(D10Rat219-D10Rat29) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 10 60.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67873 829
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 16 87.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67852 829
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 62.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67855 829
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 12 8.3 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68195 829
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 10 70.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68198 829
DA.ACI-(D10Rat15-D10Rat29) experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 4 8.7 d 2.8 5.6 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68212 829
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 10 30.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68213 829
DA.ACI-(D10Rat219-D10Rat29) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 10 40.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68216 829
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 75.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68735 829
DA.ACI-(D10Rat219-D10Rat29) experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 13 7.4 d 1.2 4.33 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68230 829
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 10 80.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67849 829